---
title: Using Self-evaluation to Increase Visit Intervals in Juvenile Idiopathic Arthritis
nct_id: NCT05603286
overall_status: COMPLETED
phase: NA
sponsor: Joeri van Straalen
study_type: INTERVENTIONAL
primary_condition: JIA
countries: Netherlands
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05603286.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05603286"
ct_last_update_post_date: 2023-05-09
last_seen_at: "2026-05-12T06:18:45.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Using Self-evaluation to Increase Visit Intervals in Juvenile Idiopathic Arthritis

**Official Title:** Testing an Increased Visit Interval scHeme UsIng Web-based Self-evaluation in Patients With Juvenile Idiopathic Arthritis

**NCT ID:** [NCT05603286](https://clinicaltrials.gov/study/NCT05603286)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 85
- **Lead Sponsor:** Joeri van Straalen
- **Conditions:** JIA, Self-Evaluation
- **Start Date:** 2022-03-28
- **Completion Date:** 2023-04-01
- **CT.gov Last Update:** 2023-05-09

## Brief Summary

In the THUIS study, JIA patients in clinical remission will skip one 3-monthly hospital control visit and instead monitor their disease activity at home. Outcomes at 6 months will be compared to those from a historical cohort.

## Detailed Description

Background:

Children with juvenile idiopathic arthritis (JIA) commonly visit their pediatric rheumatologist every 3 months. This costs time and money for the patient, their parents or guardian, the hospital and other stakeholders. Therefore, the THUIS study aims to demonstrate that JIA patients in clinical remission can safely increase their visit interval by home-monitoring disease activity using the EuroQol five-dimensional youth questionnaire with five levels (EQ-5D-Y-5L) and Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

Methods:

JIA patients in remission from the Wilhelmina Children's Hospital in Utrecht, the Netherlands, will skip one 3-monthly control visit and instead complete an online EQ-5D-Y-5L and JAMAR questionnaire at home. The home-monitoring results will be evaluated by a research nurse in consultation with the treating pediatric rheumatologist in order to determine if the patient can safely remain at home or has to be planned in for a short-term control visit at the hospital. Primary and secondary outcomes after 6 months will be compared with a historical cohort of matched JIA patients in order to prove non-inferiority.

## Eligibility

- **Minimum age:** 6 Years
- **Maximum age:** 20 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* JIA diagnosis of ≥1 year, all subtypes can participate
* Clinical remission, defined as a cJADAS of ≤3

Exclusion Criteria:

* Insufficient control of the Dutch language
* Not able or willing to use e-mail
```

## Arms

- **Home-monitoring arm** (EXPERIMENTAL) — After inclusion, participants will skip one regular 3-monthly control visit and instead complete an online EQ-5D-Y-5L and JAMAR questionnaire. 5-7 months after inclusion, participants will be followed-up at the hospital and complete a questionnaire about their experiences with home-monitoring.

## Interventions

- **Home-monitoring** (PROCEDURE) — Questionnaires for home-monitoring will be send to the participants 11 weeks after the baseline visit via e-mail using Castor EDC and can be completed using a computer, tablet or smartphone. Home-monitoring can be done together with a parent or guardian, if needed.

## Primary Outcomes

- **Disease flares** _(time frame: 5-7 months after inclusion.)_ — The number of disease flares 6 months after baseline visit. A disease flare is defined as a cJADAS score of \>3.

## Secondary Outcomes

- **Rescheduled visits** _(time frame: Through study completion, an average of 6 months)_
- **Disease flares at rescheduled visits** _(time frame: Through study completion, an average of 6 months)_
- **Adverse events** _(time frame: Through study completion, an average of 6 months)_
- **Patient satisfaction** _(time frame: 5-7 months after inclusion.)_
- **Reminders** _(time frame: Through study completion, an average of 6 months)_
- **Failure** _(time frame: Through study completion, an average of 6 months)_

## Locations (1)

- University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university medical center utrecht, wilhelmina children's hospital|utrecht||netherlands` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05603286.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05603286*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*